Display options
Cite
Kaufmann SHE, Dockrell HM, Drager N, et al. TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. Front Immunol. 2017;8:1203doi: 10.3389/fimmu.2017.01203.
Kaufmann, S. H. E., Dockrell, H. M., Drager, N., Ho, M. M., McShane, H., Neyrolles, O., Ottenhoff, T. H. M., Patel, B., Roordink, D., Spertini, F., Stenger, S., Thole, J., Verreck, F. A. W., Williams, A. (2017). TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. Frontiers in immunology, 81203. https://doi.org/10.3389/fimmu.2017.01203
Kaufmann, Stefan H E, et al. "TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development." Frontiers in immunology vol. 8 (2017): 1203. doi: https://doi.org/10.3389/fimmu.2017.01203
Kaufmann SHE, Dockrell HM, Drager N, Ho MM, McShane H, Neyrolles O, Ottenhoff THM, Patel B, Roordink D, Spertini F, Stenger S, Thole J, Verreck FAW, Williams A. TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. Front Immunol. 2017 Oct 04;8:1203. doi: 10.3389/fimmu.2017.01203. eCollection 2017. PMID: 29046674; PMCID: PMC5632681.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2017 Oct 04;8:1203. doi: 10.3389/fimmu.2017.01203. eCollection 2017.

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development.

Frontiers in immunology

Stefan H E Kaufmann, Hazel M Dockrell, Nick Drager, Mei Mei Ho, Helen McShane, Olivier Neyrolles, Tom H M Ottenhoff, Brij Patel, Danielle Roordink, François Spertini, Steffen Stenger, Jelle Thole, Frank A W Verreck, Ann Williams,

Affiliations

  1. Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.
  2. Immunology and Infection Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  3. Tuberculosis Vaccine Initiative (TBVI), Lelystad, Netherlands.
  4. Bacteriology Division, MHRA-NIBSC, Potters Bar, United Kingdom.
  5. University of Oxford, Oxford, United Kingdom.
  6. Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
  7. Leiden University Medical Center, Leiden, Netherlands.
  8. RegExcel Consulting Ltd, Surrey, United Kingdom.
  9. Centre Hospital Universitaire Vaudois, Lausanne, Switzerland.
  10. University Hospital of Ulm, Ulm, Germany.
  11. Biomedical Primate Research Centre, Rijswijk, Netherlands.
  12. Public Health England, London, United Kingdom.

PMID: 29046674 PMCID: PMC5632681 DOI: 10.3389/fimmu.2017.01203

Abstract

TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

Keywords: bacille Calmette–Guérin; biomarker; clinical trial; discovery; portfolio management; tuberculosis; vaccination

References

  1. J Clin Invest. 2013 Feb;123(2):712-26 - PubMed
  2. Am J Respir Crit Care Med. 2016 Aug 1;194(3):345-55 - PubMed
  3. Tuberculosis (Edinb). 2017 May;104:46-57 - PubMed
  4. Microbiol Spectr. 2016 Oct;4(5):null - PubMed
  5. BMC Med. 2016 May 16;14 :76 - PubMed
  6. PLoS Pathog. 2016 Jul 28;12 (7):e1005770 - PubMed
  7. Infect Immun. 2015 May;83(5):2118-26 - PubMed
  8. MBio. 2014 Jun 03;5(3):e01262-14 - PubMed
  9. Nat Commun. 2016 Apr 12;7:11290 - PubMed
  10. PLoS One. 2015 Sep 14;10(9):e0138042 - PubMed
  11. Clin Biochem. 2011 Oct;44(14-15):1241-6 - PubMed
  12. J Clin Immunol. 2013 Nov;33(8):1360-75 - PubMed
  13. Vaccine. 2015 Nov 27;33(48):6800-8 - PubMed
  14. Expert Rev Vaccines. 2014 May;13(5):619-30 - PubMed
  15. Vaccine. 2006 Apr 24;24(17):3408-19 - PubMed
  16. Mucosal Immunol. 2013 Sep;6(5):972-84 - PubMed
  17. PLoS One. 2014 Feb 26;9(2):e89612 - PubMed
  18. Vaccine. 2016 Oct 17;34(44):5298-5305 - PubMed
  19. Expert Rev Vaccines. 2017 Jun;16(6):565-576 - PubMed
  20. Mucosal Immunol. 2017 Mar;10 (2):555-564 - PubMed
  21. Nat Chem Biol. 2014 Nov;10(11):950-6 - PubMed
  22. Microbiol Spectr. 2017 Jan;5(1):null - PubMed
  23. Vaccine. 2005 Feb 3;23(11):1393-8 - PubMed
  24. J Infect Dis. 2016 Mar 1;213(5):831-9 - PubMed
  25. Clin Vaccine Immunol. 2013 May;20(5):663-72 - PubMed
  26. Vaccine. 2014 Sep 8;32(40):5192-7 - PubMed
  27. Vaccine. 2014 Oct 29;32(47):6240-50 - PubMed
  28. Nat Med. 2014 Jan;20(1):75-9 - PubMed
  29. Sci Rep. 2016 Nov 28;6:37793 - PubMed
  30. Vaccine. 2013 Nov 12;31(47):5602-20 - PubMed
  31. EBioMedicine. 2014 Dec 02;2(2):172-9 - PubMed
  32. Vaccine. 2015 Mar 10;33(11):1353-9 - PubMed
  33. Expert Rev Vaccines. 2017 Aug;16(8):845-853 - PubMed
  34. Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):E989-97 - PubMed
  35. Tuberculosis (Edinb). 2006 May-Jul;86(3-4):303-9 - PubMed
  36. PLoS One. 2010 Jan 01;5(1):e8527 - PubMed
  37. PLoS One. 2017 Feb 16;12 (2):e0171358 - PubMed
  38. Tuberculosis (Edinb). 2012 Mar;92 Suppl 1:S6-13 - PubMed
  39. Nat Med. 2004 Sep;10(9):935-41 - PubMed
  40. PLoS One. 2015 Dec 16;10(12):e0145234 - PubMed
  41. Tuberculosis (Edinb). 2016 Sep;100:118-27 - PubMed
  42. Lancet Infect Dis. 2014 Oct;14(10):939-46 - PubMed
  43. PLoS Pathog. 2015 Mar 24;11(3):e1004671 - PubMed
  44. Vaccine. 2009 Apr 6;27(16):2282-8 - PubMed
  45. Immunol Rev. 2015 Mar;264(1):167-81 - PubMed
  46. PLoS One. 2009;4(4):e5264 - PubMed
  47. Vaccine. 2014 Feb 7;32(7):779-84 - PubMed
  48. J Infect Dis. 2014 Feb 15;209(4):500-9 - PubMed
  49. Clin Vaccine Immunol. 2014 Apr;21(4):594-7 - PubMed
  50. Vaccine. 2011 Jul 1;29 Suppl 1:A37-9 - PubMed
  51. PLoS Pathog. 2016 Jun 15;12 (6):e1005687 - PubMed
  52. J Intern Med. 2014 May;275(5):467-80 - PubMed
  53. Nat Med. 2011 Feb;17(2):189-94 - PubMed
  54. PLoS One. 2015 Oct 28;10(10):e0141577 - PubMed
  55. Tuberculosis (Edinb). 2015 Jul;95(4):452-62 - PubMed
  56. Hum Vaccin Immunother. 2016 Nov;12 (11):2813-2832 - PubMed
  57. Int J Infect Dis. 2017 Mar;56:263-267 - PubMed
  58. Sci Transl Med. 2015 Feb 25;7(276):276fs8 - PubMed
  59. Mol Cell Proteomics. 2015 Dec;14 (12 ):3105-17 - PubMed
  60. Eur J Immunol. 2015 Apr;45(4):1069-81 - PubMed
  61. Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):85-96 - PubMed
  62. Vaccine. 2015 Sep 29;33(40):5282-8 - PubMed
  63. Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):29-38 - PubMed
  64. Scand J Immunol. 2016 Dec;84(6):344-352 - PubMed
  65. PLoS One. 2012;7(8):e43285 - PubMed
  66. MBio. 2016 May 24;7(3): - PubMed
  67. Int J Infect Dis. 2017 Mar;56:253-257 - PubMed
  68. Lancet. 2013 Mar 23;381(9871):1021-8 - PubMed
  69. PLoS One. 2009 Nov 24;4(11):e7972 - PubMed
  70. J Infect Dis. 2012 May 1;205(9):1425-35 - PubMed
  71. Int J Infect Dis. 2017 Mar;56:268-273 - PubMed
  72. Vaccine. 2013 Oct 1;31(42):4867-73 - PubMed
  73. PLoS Pathog. 2012;8(5):e1002607 - PubMed
  74. Am J Respir Crit Care Med. 2013 Sep 15;188(6):724-32 - PubMed
  75. Lancet Respir Med. 2015 Dec;3(12 ):953-62 - PubMed
  76. Infect Dis Rep. 2016 Jun 24;8(2):6568 - PubMed
  77. Vaccine. 2010 Mar 8;28(11):2259-70 - PubMed
  78. Lancet. 2016 Jun 4;387(10035):2312-2322 - PubMed
  79. Tuberculosis (Edinb). 2012 Mar;92 Suppl 1:S25-9 - PubMed
  80. Thorax. 2016 Sep;71(9):785-94 - PubMed
  81. Eur Respir J. 2016 Dec;48(6):1751-1763 - PubMed
  82. J Infect Dis. 2013 Jan 1;207(1):18-29 - PubMed
  83. Clin Vaccine Immunol. 2011 Jun;18(6):907-13 - PubMed
  84. J Innate Immun. 2017;9(2):162-180 - PubMed
  85. EMBO Mol Med. 2015 Dec 18;8(2):86-95 - PubMed
  86. PLoS One. 2015 Nov 24;10(11):e0143552 - PubMed
  87. EBioMedicine. 2015 Nov;2(11):1619-26 - PubMed
  88. Cell Rep. 2017 Mar 14;18(11):2752-2765 - PubMed
  89. J Clin Invest. 2005 Sep;115(9):2472-9 - PubMed
  90. Pathog Dis. 2016 Jun;74(4):ftw016 - PubMed
  91. PLoS Med. 2013 Oct;10(10):e1001538 - PubMed
  92. Vaccine. 2016 Sep 7;34(39):4656-4665 - PubMed
  93. Immunol Lett. 2016 Jul;175:50-7 - PubMed

Publication Types